• Worg Pharmaceuticals

  Participated · Series D · Dec 2025

  Founded in 2018, Worg Pharmaceuticals is focused on creating innovative, safe and effective immunotherapy treatments targeting allergies and autoimmune diseases. Headquartered in Shanghai with an operational center in Basel, the company leverages two proprietary technology platforms, PCFiT and Apitope, to rapidly build its R&D pipeline. In addition to in-house development, Worg pursues external collaborations to enrich its portfolio and accelerate commercialization. The firm is also advancing a self-developed molecular allergy-diagnostics platform to complement its therapeutic offerings. Its management team draws experience from leading global life-science organizations such as Roche, Johnson & Johnson, Alexion, Shire, the FDA, Aventis, GSK, Boteng and Fosun. With these capabilities, Worg aims to evolve into a fully integrated, globally operating pharmaceutical company. No revenue or patient-usage metrics were disclosed in the article.

• Huasun Energy

  Participated · Series C · Nov 2023

  Founded in July 2020 and based in Xuancheng, Anhui, Huasun specializes in R&D, production and sales of high-efficiency silicon heterojunction (HJT) cells and modules. The company supplies HJT wafers, cells and modules to module manufacturers and power-station operators both in China and abroad. Huasun reports strong process metrics on ultra-thin silicon: 130µm wafers with yields above 95.5%, 110µm and 120µm mass-production processes stabilized with yields above 95%, and 100µm wafer mass-production testing underway. Management plans accelerated construction at production bases in Xuancheng, Dali, Wuxi and Hefei and expects to achieve roughly 20GW of cell capacity and 20GW of module capacity within the year. The company is pursuing advanced R&D including HJT–perovskite tandem cells alongside capacity expansion. Recent fundraising has been directed toward continued HJT product scale-up and front‑end technology development.

No current team members are available.